Thermo Fisher Scientific Transplant diagnostics revenue
Transplant diagnostics revenue at Thermo Fisher Scientific came to $131.0M for the quarter to 26 Sep 2026, up 4.8% from a year earlier.
As Thermo Fisher Scientific reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.
By quarter
| Period ending | Transplant diagnostics revenue | Change on a year | Filed |
|---|---|---|---|
| 26 Sep 2026 | $131.0M | up 4.8% | 30 Oct 2026 |
| 27 Jun 2026 | $134.0M | up 8.1% | 31 Jul 2026 |
| 28 Mar 2026 | $121.0M | up 7.1% | 1 May 2026 |
| 31 Dec 2025 | $130.0M | — | 26 Feb 2026 |
| 27 Sep 2025 | $125.0M | up 9.6% | 31 Oct 2025 |
| 28 Jun 2025 | $124.0M | up 11.7% | 1 Aug 2025 |
| 29 Mar 2025 | $113.0M | — | 2 May 2025 |
| 28 Sep 2024 | $114.0M | — | 1 Nov 2024 |
| 29 Jun 2024 | $111.0M | — | 2 Aug 2024 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Thermo Fisher Scientific: Organic revenue (change on a year) · Remaining performance obligations · Product revenues · Service revenues · Consumables revenue · Instruments revenue · Clinical research revenue · Research and safety market channel revenue · Pharma services revenue · Biosciences revenue · BioProduction revenue · Chromatography and mass spectrometry revenue · Electron microscopy revenue · Genetic sciences revenue · Laboratory products revenue · Healthcare market channel revenue · Chemical analysis revenue · Clinical diagnostics revenue · ImmunoDiagnostics revenue · Microbiology revenue · Laboratory Products and Biopharma Services revenue · Life Sciences Solutions revenue · Analytical Instruments revenue · Specialty Diagnostics revenue · financial statements
Every KPI and segment of TMO, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.